Dr. Jörn Drappa is a physician-scientist with more than two decades of experience spanning clinical development, translational research, and regulatory strategy in immunology and inflammatory diseases. He received his M.D. from the University of Heidelberg and a Ph.D. in molecular immunology from the University of Oxford, where his work centered on T-cell signaling pathways. Before entering industry, he held faculty appointments at leading academic medical centers and led investigator-initiated trials that advanced understanding of cytokine-driven autoimmune conditions. Dr. Drappa has played key roles in the development and approval of several first-in-class therapeutics while serving in senior clinical leadership positions at Genentech and Principia Biopharma. His contributions include designing pivotal Phase 3 programs, authoring more than 60 peer-reviewed publications, and securing multiple patents on targeted kinase inhibitors. These achievements have been recognized through industry awards for excellence in clinical innovation and patient-focused drug development. As Chief Medical Officer at Alumis Inc., Dr. Drappa directs all clinical and medical affairs activities, shaping the company’s strategy for its pipeline of next-generation therapies aimed at autoimmune and inflammatory disorders. He oversees global clinical trials, medical governance, and interactions with regulatory authorities, ensuring that scientific rigor and patient safety remain central to Alumis’ mission of delivering transformative treatments.